IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study

1. Phillips, T.
2. Jurczak, W.
3. Ribrag, V.
4. Linton, K.
5. Collin, G.P.
6. Lopéz-Jimenéz, J.
7. Reddy, N.
8. Mengarelli, A.
9. Musuraca, G.
10. Sheehy, O.
11. Xu, W.
12. Azoulay, M.
13. Ghalie, R.G.
14. Zinzani, P.L.
15. Zelenetz, A.D.